|
Explanation of Responses:
|
|
(
1)
|
Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $191,381.19 cash, (b) 23,007 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c)140,206 contingent value rights, which represent the right to receive possible additional cash payments.
|
|
(
2)
|
This option, which was 100% vested on November 15, 2006, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $147,760.15, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 34,882 contingent value rights, which represents the right to receive possible additional future cash payments.
|
|
(
3)
|
This option, which was 100% vested on July 13, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $168,296.28, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 39.730 contingent value rights, which represents the right to receive possible additional future cash payments.
|
|
(
4)
|
This option, which was 100% vested on July 13, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $56,103.31, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 13,243 contingent value rights, which represents the right to receive possible additional future cash payments.
|
|
(
5)
|
This option, which was 100% vested on January 1, 2006, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $3,261.72, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 770 contingent value rights, which represents the right to receive possible additional future cash payments.
|
|
(
6)
|
This option, which was 100% vested on July 13, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $36,812.95, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 19,865 contingent value rights, which represents the right to receive possible additional future cash payments.
|
|
(
7)
|
This option, which was 100% vested on January 1, 2007, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
|
|
(
8)
|
This option, which was 100% vested on January 1, 2010, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
|
|
(
9)
|
This option, which was 100% vested on July 13, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
|
|
(
10)
|
This option, which provided for vesting at the rate of 1/48th on February 1, 2008, and 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2012, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
|
|
(
11)
|
This option, which provided for vesting at the rate of 1/48th on February 1, 2009, and then 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2013, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $161,000, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 50,000 contingent value rights, which represents the right to receive possible additional future cash payments.
|
|
(
12)
|
This option, which provided for vesting at the rate of 1/36th on August 27, 2009, and then 1/36th monthly thereafter, such that all of the shares would be fully vested as of July 27, 2012, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $88,550, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b)27,500 contingent value rights, which represents the right to receive possible additional future cash payments.
|
|
(
13)
|
This option, which provided for vesting at the rate of 1/48th on February 1, 2010, and then 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2014, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $32,850, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 45,000 contingent value rights, which represents the right to receive possible additional future cash payments.
|